Scholars Central

Conference abstractPublished 10 Sep 2018

Cannabidiol (CBD): The evidence base

Authors: Kevin Spelman

Chief Scientific Officer, Indomira Ltd., New Zealand

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Beyond THC there are at least 60 other cannabinoids in the Cannabis plant. Unfortunately the fascination and politics around THC, have created a potential bias against the pharmacology of other potentially therapeutic cannabidnoids. Cannabidiol (CBD) is the second most plentiful cannabinoid in the Cannabis species. Importantly, this pleiotropic cannabinoid does not induce euphoria but does show some intriguing activity in a number of molecular pathways, tissues and physiological systems. Beyond attenuating the euphoria of THC, anxiolytic, anti-inflammatory, analgesic, anti-seizure, anti-addictive and anti-neoplastic activities are prominent. In addition, it puts other receptors into play besides the the classical cannabinoid receptors (CB1 and CB2). which is growing rapidly and offers broad spectrum and potentailly significant therapeutic potential.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Alternative & Integrative Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalAlternative & Integrative Medicine
  • SubjectAlternative & Palliative Care
  • BylineArticles whose byline prints “Kevin Spelman”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels